CRISPR Therapeutics AG

NasdaqGM:CRSP Stock Report

Market Cap: US$5.6b

CRISPR Therapeutics Dividend

Dividend criteria checks 0/6

CRISPR Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.7%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$1.91
Dividend yield forecast in 3Y0%

Recent dividend updates

No updates

Recent updates

Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape

Mar 26

There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump

Feb 22
There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump

Crispr Therapeutics: Cautiously Optimistic

Feb 22

Crispr Therapeutics: Investors Bet Against Casgevy Uptake

Feb 01

Crispr Therapeutics: Commercial Validation Is The Next Step

Jan 18

Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry

Jan 11

CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing

Dec 25
CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing

CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

Nov 02
CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Oct 05
A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price

Sep 14
CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price

We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate

Jul 24
We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate

Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Jun 28
Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

Apr 02
CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 06
CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price

Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth

Dec 08
Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth

CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag

Sep 28

Crispr: Elucidating And Forecasting Key Developments

Sep 21

Crispr Therapeutics: Nearing Harvest Season

Sep 08

Crispr Therapeutics: Unlikely To Fall To May Lows, But Not The Time To Buy Yet (Technical Analysis)

Aug 25

News Flash: Analysts Just Made A Noticeable Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Forecasts

Aug 09
News Flash: Analysts Just Made A Noticeable Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Forecasts

CRISPR Therapeutics GAAP EPS of -$2.40 misses by $0.19, revenue of $0.16M misses by $2.04M

Aug 08

Crispr Therapeutics' Continued Progress Warrants A Buy

Jul 25

Crispr Therapeutics: Innovation Day Showcases Upside Opportunities In Short And Long Term

Jun 23

Crispr Therapeutics: Progress, Risk, And Reward

Apr 27

The Commercial Potential Of Crispr In Light Of Patent Challenges

Mar 22

Bad News may be Good for Long Term Investors - Analyzing the Key Risks of CRISPR Therapeutics AG (NASDAQ:CRSP)

Mar 10
Bad News may be Good for Long Term Investors - Analyzing the Key Risks of CRISPR Therapeutics AG (NASDAQ:CRSP)

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if CRSP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRSP's dividend payments have been increasing.


Dividend Yield vs Market

CRISPR Therapeutics Dividend Yield vs Market
How does CRSP dividend yield compare to the market?
SegmentDividend Yield
Company (CRSP)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.7%
Analyst forecast in 3 Years (CRSP)0%

Notable Dividend: Unable to evaluate CRSP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CRSP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate CRSP's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CRSP has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.